As the transition in gene and pathways profiles correlated with the levels of TMEM230 expression, our results support that TMEM230 is a novel clinical marker that may differentiate GBM from LGG tumor properties for application in patient diagnostics and prognosis. This evidence concerns the gene TMEM230 and glioblastoma.